Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma

Loncastuximab tesirine-lpyl (formerly ADCT-402) is an antibody-drug conjugate (ADC) comprising a humanised anti-CD19 monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer-based payload tesirine. Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.2273-2273
Hauptverfasser:	Sachini, Nikoleta, Jabeen, Asma, van Berkel, Patrick H, Zammarchi, Francesca
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!